Overview

Human Behavioral Pharmacology Laboratory (HBPL) Study of Varenicline's Impact on Cocaine and Alcohol Craving

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II within-subjects double-blind placebo-controlled human laboratory study. The purpose of the study is to determine the efficacy of varenicline (Chantix) for reducing cue-induced cocaine and alcohol craving.
Phase:
Phase 2
Details
Lead Sponsor:
Jennifer Plebani
University of Pennsylvania
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Varenicline